LONDON, UK: Ashington Innovation plc has entered into a non-binding heads of terms agreement with Calon Cardio-Technology Limited, to acquire 100% of the outstanding shares in Calon in an all-share transaction. The acquisition is subject to the completion of the proposed reverse takeover of Cell Therapy Limited (CTL) announced on 19th August 2023 as well…
LONDON, UK: Ashington Innovation (LSE:ASHI), a SPAC that focuses on technology businesses, has announced that it has signed a non-binding term sheet to acquire Cell Therapy Limited, a clinical stage biotechnology firm with a portfolio of patented cellular medicines. Cell Therapy is developing novel therapies for heart failure, based on its proprietary technology that uses…
LONDON, UK: Ashington Innovation plc, a special purpose acquisition company (“SPAC”) aiming to benefit from favourable price conditions for companies in the financial services technology (fintech) and deep technology (deep tech) sectors, has announced the results of its initial public offering and standard listing on the Main Market of the London Stock Exchange (“the Offering”)….